Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)

Business

The FDA grants accelerated nod to Seagen (SGEN) and Genmab’s Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease…

Previous Post: Molecular Templates Inc. (MTEM) Moves 11.8% Higher: Will This Strength Last?

Next Post: Why Bryson DeChambeau, Brooks Koepka insist feud will be ‘non-issue’ at 2021 Ryder Cup

Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)

Leave a Reply Cancel reply